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AGEs activate mesangial TGF-b–Smad signaling via an an-
giotensin II type I receptor interaction.
Background. The renin-angiotensin system (RAS) and the
accumulation of advanced glycation end products (AGEs) have
been implicated in the pathogenesis of diabetic nephropathy.
Whether there is a functional interaction between the RAS and
AGEs in diabetic nephropathy is not known. In this study, we in-
vestigated whether AGEs could activate autocrine angiotensin
II (Ang II) signaling and subsequently induce transforming
growth factor-b (TGF-b)–Smad signaling in cultured rat mesan-
gial cells.
Methods. The intracellular formation of reactive oxygen
species (ROS) was detected using the fluorescent probe CM-
H2DCFDA. Ang II was measured by radioimmunoassay.
TGF-b released into media was quantitatively analyzed in
an enzyme-linked immunosorbent assay (ELISA). Smad2,
p27Kip1 (p27), fibronectin, and receptor for AGEs (RAGE)
protein expression were determined by Western blot analysis.
TGF-b–inducible promoter activity was analyzed by a luciferase
assay. DNA synthesis was evaluated by 5-bomo-2′-deoxyuridine
(BrdU) incorporation and de novo protein synthesis was deter-
mined by [3H]leucine incorporation.
Results. AGEs increased intracellular ROS generation in
mesangial cells, and this effect was significantly inhibited by an
antiserum against RAGE. AGEs also were found to stimulate
Ang II production in a time- and dose-dependent manner, which
was completely prevented by an antioxidant, N-acetylcysteine
(NAC). AGE-induced TGF-b overproduction was completely
blocked by candesartan, an Ang II type 1 receptor (AT1R) an-
tagonist. Both candesartan and neutralizing antibody against
TGF-b completely prevented AGEs-induced Smad2 phospho-
rylation and TGF-b–inducible promoter activity. Furthermore,
AGEs were found to inhibit DNA synthesis and to stimulate
de novo protein synthesis and fibronectin production in associ-
ation with up-regulation of p27. All of these phenomena were
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completely prevented by candesartan or a polyclonal antibody
against TGF-b .
Conclusion. The present study suggests that AGE-RAGE–
mediated ROS generation activates TGF-b–Smad signaling
and subsequently induces mesangial cell hypertrophy and fi-
bronectin synthesis by autocrine production of Ang II. This
pathway may provide an important link between metabolic and
haemodynamic factors in promoting the development and pro-
gression of diabetic nephropathy.
Diabetic nephropathy is a leading cause of end-stage
renal disease (ESRD), and accounts for significant mor-
bidity and mortality in patients with diabetes [1, 2]. The
development of diabetic nephropathy is characterized
by glomerular hyperfiltration, hypertrophy of glomeru-
lar and tubuloepithelial components, and thickening of
glomerular basement membranes (GBMs), followed by
an expansion of extracellular matrix (ECM) in mesangial
areas and an increased albumin excretion rate. Diabetic
nephropathy ultimately progresses to glomerular sclero-
sis associated with renal dysfunction [3].
There is a growing body of evidence suggesting that
the intrarenal renin-angiotensin system (RAS) plays an
important role not only in the regulation of glomerular
hemodynamics but also in glomerular hypertrophy and
sclerosis [4, 5]. Indeed, blockade of the RAS with drugs
such as angiotensin-converting enzyme (ACE) inhibitors
and angiotensin II (Ang II) type 1 receptor (AT1R) an-
tagonists was found to suppress the development and pro-
gression of diabetic nephropathy in both type 1 and type
2 diabetic patients [6–8]. Furthermore, several in vitro
and in vivo studies have implicated transforming growth
factor-b (TGF-b), a fibrogenic cytokine, as a key medi-
ator in advanced diabetic renal disease, and the proscle-
rotic action of Ang II is mediated, at least in part, by
TGF-b [9–13].
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Reducing sugars react nonenzymatically with the
amino groups of proteins to initiate a complex series
of rearrangements and dehydrations to produce a class
of irreversibly cross-linked, fluorescent moieties termed
advanced glycation end products (AGEs) [14–16]. The
formation and accumulation of AGEs are characteristic
features of aged or diabetic tissues and these products
also have been strongly implicated in the pathogenesis
of diabetic micro- and macrovascular complications [16–
24]. In fact, there is compelling evidence to suggest that
the formation and accumulation of AGEs mediate the
progressive alteration in renal architecture and loss of
renal function and that inhibitors of advanced glycation
prevent the progression of experimental diabetic
nephropathy [25–33]. Whether there is a functional in-
teraction between the RAS-TGF-b system and AGE-
mediated signaling pathways in diabetic nephropathy is
not known. In this study, we investigated whether AGEs
could activate autocrine Ang II signaling and subse-
quently induce TGF-b–Smad signaling in cultured rat
mesangial cells. We further examined the involvement
of the receptor for AGEs (RAGE) and reactive oxygen
species (ROS) generation in the deleterious effects of
AGEs.
METHODS
Materials
Bovine serum albumin (BSA) (fraction V) and a
monoclonal antibody against mouse b-actin were pur-
chased from Sigma Chemical Co. (St. Louis, MO, USA).
D-glyceraldehyde and N-acetylcysteine (NAC) were
from Nakalai Tesque (Kyoto, Japan). Candesartan, an
AT1R antagonist, was provided by Takeda Chemical In-
dustries, Ltd. (Osaka, Japan). A polyclonal antibody di-
rected against phosphorylated Smad2 was a gift from
Dr. Peter ten Dijke (Division of Cellular Biochem-
istry, The Netherlands Cancer Institute, Amsterdam,
The Netherlands). Human recombinant TGF-b and a
polyclonal antibody against TGF-b for neutralizing as-
says were from R&D Systems (Minneapolis, MN, USA).
[3H]leucine was from Amersham Bioscience (Bucking-
hamshire, UK). Goat polyclonal IgG against RAGE
(sc-8230) and rabbit polyclonal IgG against p27Kip1 (p27)
(sc-528) were from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA). Antiserum against human RAGE for
neutralizing assays, which recognizes the amino acid
residues 167 to 180 of human RAGE protein, was pre-
pared as described previously [34]. A polyclonal antibody
against rabbit fibronectin was obtained from Chemicon
International, Inc. (Temecula, CA, USA). Polyclonal an-
tibody against glyceraldehyde-derived AGEs that did not
cross-react with well defined AGE epitopes and antibod-
ies against carboxymethyllysine (CML) for neutralizing
assays were prepared as described previously [27, 35].
Preparation of AGE-BSA and CML-BSA and
purification of AGEs from human serum
AGE-BSA was prepared as described previously [35].
Briefly, BSA was incubated under sterile conditions with
0.1 mol/L D-glyceraldehyde in 0.2 mol/L phosphate-
buffered saline (PBS) (pH 7.4) for 7 days. Unincorpo-
rated sugars were then removed by dialysis against PBS.
Nonglycated BSA was incubated in the same conditions
except for the absence of D-glyceraldehyde as a nega-
tive control. Preparations were tested for endotoxin us-
ing Endospecy ES-20S system (Seikagaku Co., Tokyo,
Japan) and no endotoxin was detected. The extent of
chemical modification was determined as described with
2,4,6-trinitrobenzenesulfonic acid as a difference in ly-
sine residues of modified and unmodified protein prepa-
rations [36]. The extent of lysine modification (%) of
modified BSA preparation was 65% for glyceraldehyde-
derived AGE-BSA. The concentration of AGEs used in
this experiment was comparable with that of in vivo situ-
ation of diabetes [35].
CML-BSA (CML) was prepared as described previ-
ously [35]. Briefly, 50 mg/mL protein was incubated at
37◦C for 24 hours with 45 mmol/L glyoxylic acid and
150 mmol/L NaCNBH3 in 2 mL of 0.2 mol/L phosphate
buffer (pH 7.4), followed by PD-10 column chromatog-
raphy and dialysis against PBS.
Serum AGEs fractions were obtained from diabetic pa-
tients on maintenance hemodialysis and from normal vol-
unteers at Suiyukai Clinic, as described previously [37].
Informed consent was obtained from all the subjects.
Cells
Mesangial cells were obtained by culturing glomeruli
isolated from the kidneys of 200 to 250 g male Wistar
rats by a conventional sieving method [38]. All
surgical interventions and anesthesia were conducted ac-
cording to institutional guidelines and in compliance with
international laws and policies (EEC Council Directive
86/609, OJL 358, December 1987; Guide for the Care
and Use of Laboratory Animals, NIH Publication No. 85-
23, 1985). The cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Nissui Pharmaceutial Co.,
Tokyo, Japan) supplemented with 10% fetal calf serum
(FCS) (Filtron Pty Ltd., Brooklyn, Australia), 2 mmol/L
L-glutamine, 100 U/mL penicillin, and 100 lg/mL strepto-
mycin. Mesangial cells at less than 10 passages were used
for the experiments. AGE treatments were carried out in
a medium containing 0.5% FCS.
Measurement of intracellular ROS generation
The intracellular formation of ROS was detected us-
ing the fluorescent probe CM-H2DCFDA (Molecular
Probes, Inc., Eugene, OR, USA) as described previously
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[39]. Briefly, cells were plated at 5 × 103 cells/well in
96-well plates. The cells were loaded with 10 lmol/L
CM-H2DCFDA, incubated for 60 minutes at 37◦C, and
analyzed with an EZS-FL fluorescent plate reader (Asahi
Techno Glass, Tokyo, Japan) using EZScan-FL for Win-
dows program.
Measurement of Ang II
Cells were plated at 5 × 105 cells/well in 6-well plates.
The next day, the cells were rested in a serum-free
medium for 24 hours, and then treated with various con-
centrations of AGEs in the presence or absence of 1
mmol/L NAC for the various time periods. After incuba-
tion, cells were lysed and Ang II levels in the cell lysates
were measured by a radioimmunoassay system according
to the method of Kashiwagi et al [40].
Measurement of TGF-b
Cells were plated at 5 × 103 cells/well in 96-well
plates. The next day, the cells were rested in a serum-free
medium for 24 hours, and then treated with 100 lg/mL
of AGE-BSA or nonglycated BSA in the presence or
absence of 10−7 mol/L candesartan for 48 hours. Total
TGF-b released into the media was measured by an
enzyme-linked immunosorbent assay (ELISA) system
(Promega, Madison, WI, USA).
Western blot analysis for phosphorylated Smad2,
cyclin-dependent kinase inhibitor, p27, fibronectin,
and RAGE proteins
Mesangial cells were treated with the various con-
centrations of AGEs, 100 lg/mL of nonglycated BSA,
100 lg/mL of CML, 500 lg/mL of purified-AGEs from
human plasma, or 10 ng/mL of TGF-b in the presence
or absence of 10−7 mol/L candesartan or 10 lg/mL of
polyclonal antibody against TGF-b for 48 hours. The
cells were then lysed and 30 lg/mL of proteins were
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to
polyvinylidine difluoride (PVDF) membranes
(ImmobilonTM) (Millipore, MA, USA). Membranes
were probed with 1:1000 dilution of polyclonal antibod-
ies against phosphorylated Smad2, p27, fibronectin, or
RAGE. The immune complexes were visualized with an
enhanced chemiluminescence detection system (ECL)
(Amersham Bioscience), as described previously [41].
Measurement of TGF-b–inducible promoter activity
Plasmid containing the TGF-b–inducible promoter
(CAGA)12 attached upstream to the luciferase reporter
gene, was the kind gift from Dr. Peter ten Dijke [42].
Mesangial cells were plated at 5 × 104 cells/well in 6-
well plates. The next day, cells were rested in a serum-
free medium for 24 hours. The cells were subsequently
transfected with luciferase-reporter plasmids (2 lg) us-
ing FuGENE 6 (Roche Diagnostics Corp., Indianapolis,
IN, USA). After transfection, the cells were treated with
100 lg/mL of AGE-BSA, 100 lg/mL of nonglycated BSA,
or 10 ng/mL of TGF-b in the presence or absence of 10−7
mol/L candesartan or 10 lg/mL of polyclonal antibody
against TGF-b for 48 hours. Luciferase activity was then
measured with a luminometer (Promega).
Measurement of 5-bromo-2′deoxyuridine (BrdU)
incorporation
Cells were plated at 5 × 103 cells/well in 96-well
plates. The next day, the cells were rested in a serum-
free medium for 24 hours, and then incubated with
100 lg/mL of AGE-BSA or nonglycated BSA in the pres-
ence or absence of 10−7 mol/L candesartan or 10 lg/mL
of polyclonal antibody against TGF-b for 24 hours. Cells
were treated with BrdU for the last 16 hours and its in-
corporation into the cells was determined using a cell
proliferation ELISA colorimetric kit (Roche).
Measurement of [3H]leucine incorporation
Cells were plated at 4 × 104 cells/well in 24-well plates.
The next day, the cells were rested in serum-free medium
for 24 hours, and then incubated with 100 lg/mL of
AGE-BSA or nonglycated BSA in the presence or ab-
sence of 10−7 mol/L candesartan or 10 lg/mL of poly-
clonal antibodies against TGF-b for 24 hours. Cells were
treated with 2 lCi/well [3H]leucine for the last 16 hours
and its incorporation into the cells was determined as
previous described [43]. The count of [3H]leucine was
divided by the cell number, which was counted using a
hemocytometer after tripan blue exclusion.
Statistical analysis
All values are presented as mean ± SEM. Experi-
mental groups were compared by analysis of variance
(ANOVA), and, when appropriate, with Scheffe’s test for
multiple comparisons. A level of P < 0.05 was accepted
as statistically significant.
RESULTS
Effects of AGEs on ROS production
As shown in Figure 1A, glyceraldehyde-derived AGEs,
a class of representative ligands for RAGE [23], dose-
dependently increased intracellular ROS generation in
mesangial cells. Compared with control conditions (treat-
ment with 100 lg/mL of nonglycated BSA), treatment
with 100 lg/mL of AGE-BSA significantly increased ROS
generation in mesangial cells by twofold. Furthermore,
a neutralizing antiserum directed against RAGE com-
pletely prevented the increase in ROS generation in
2140 Fukami et al: Role of AGE-RAGE in diabetic nephropathy
0
100
200
300
R
O
S 
ge
ne
ra
tio
n,
%
 o
f c
on
tro
l
BSA 100 µg/mL
AGE 10 µg/mL
AGE 100 µg/mL
AGE 100 µg/mL +
RAGE-antiserum
BSA 100 µg/mL +
RAGE-antiserum
(N = 6,
respectively)
*
*
#A
0
50
100
200
150
R
O
S 
ge
ne
ra
tio
n,
%
 o
f c
on
tro
l
BSA 100 µg/mL
CML 50 µg/mL
CML 100 µg/mL
(N = 6,
respectively)
B *
*
0
50
100
200
150
R
O
S 
ge
ne
ra
tio
n,
%
 o
f c
on
tro
l
BSA 100 µg/mL
AGE 100 µg/mL
AGE 100 µg/mL 
+
 anti-CML Ab
AGE 100 µg/mL 
+
 anti-AGE Ab
AGE 100 µg/mL 
+
 anti-AGE Ab
+
 anti-CML Ab
(N = 6,
respectively)
C
*
#
#
#
(N = 6,
respectively)
0
50
100
150
R
O
S 
ge
ne
ra
tio
n,
%
 o
f c
on
tro
l
AGE 100 µg/mL 
+
 anti-AGE Ab
+
 anti-CML Ab
D
Normal-frac. 500 µg/mL
AGE-frac 100 µg/mL
AGE-frac 500 µg/mL
AGE-frac. 500 µg/mL
+
 anti-CML Ab
AGE-frac. 500 µg/mL
+
 anti-AGE Ab
* #
#
#
Fig. 1. Effects of advanced glycation end products (AGEs) on reactive oxygen species (ROS) production in mesangial cells. (A) Cells were
preincubated with or without 0.1% antiserum against receptor of AGE (RAGE) 30 minutes prior to the treatment with 10 or 100 lg/mL of
AGE-bovine serum albumin (BSA) or 100 lg/mL of non-glycated BSA for 48 hours. Then ROS were quantitatively analyzed. (B) Effects of
carboxymethyllysine (CML) on ROS production in mesangial cells. Cells were incubated with 100 lg/mL of nonglycated BSA or 50 to 100 lg/mL of
CML-BSA for 48 hours. Then ROS were quantitatively analyzed. (C) Effects of neutralizing antibodies (Abs) against CML or non-CML AGEs on
ROS generation in mesangial cells. Cells were preincubated with or without 10 lg/mL of antibodies against CML (anti-CML Ab) or glyceraldehyde-
derived AGEs (anti-AGE Ab) 60 minutes prior to stimulation with 100 lg/mL of AGEs or 100 lg/mL of nonglycated BSA for 48 hours. Then
ROS were quantitatively analyzed. ∗P < 0.05 compared to the value of 100 lg/mL of nonglycated BSA; #P < 0.05 compared to the value of 100
lg/mL of AGE-BSA. (D) Effects of AGE proteins purified from diabetic patients on hemodialysis on ROS generation in mesangial cells. Cells
were preincubated with or without anti-CML Ab or anti-AGEs Ab 60 minutes prior to the treatment with 100 to 500 lg/mL of purified AGEs
from end-stage diabetic nephropathy patient (AGE-frac) or 500 lg/mL of purified AGEs from normal volunteer (normal-frac) for 48 hours. Then
ROS were quantitatively analyzed. ∗P < 0.05 compared to the value of 500 lg/mL of normal-frac; #P < 0.05 compared to the value of 500 lg/mL
of AGE-frac.
AGE-exposed cells, consistent with AGEs eliciting ROS
generation in mesangial cells through an interaction with
RAGE.
CML is reported to one of the ligands for RAGE [44].
So, we investigated whether CML is a major component
of AGEs used in this experiment that mediated the ROS
generation. CML-BSA increased ROS generation in a
dose-dependent manner (Fig. 1B). Further, neutralizing
antibodies against CML or non-CML AGEs, partially, but
significantly, inhibited the AGEs-induced ROS genera-
tion in mesangial cells (Fig. 1C). Since the AGEs effects
were completely inhibited by the additive treatments of
both antibodies, either CML or non-CML AGE compo-
nent in our AGEs preparations could stimulate the ROS
generation in mesangial cells.
We next investigated the effects of AGE proteins,
which were purified from diabetic patients on hemodial-
ysis, on ROS generation in mesangial cells. As shown
in Figure 1D, AGE proteins purified from diabetic pa-
tients significantly increased ROS generation, which was
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Fig. 2. Time-dependent effects of advanced glycation end products (AGEs) on angiotensin II (Ang II) production. (A) Cells were incubated on
6-well plates then stimulated with 100 lg/mL of nonglycated bovine serum albumin (BSA) (•) or 100 lg/mL of AGE-BSA () for the indicated
periods. (B) Dose-dependent effect of AGEs on Ang II production. Cells were treated with 100 lg/mL of nonglycated BSA or 50 to 100 lg/mL
of AGE-BSA for 48 hours. (C) Effect of an antioxidant on AGE-induced Ang II production. Cells were preincubated with or without 1 mmol/L
N-acetylcysteine (NAC) 30 minutes prior to the treatment with 100 lg/mL of AGE-BSA or nonglycated BSA for 48 hours. Ang II levels in the cell
lysate were measured in the radioimmunoassay system. ∗P < 0.05, ∗∗P < 0.01 compared to the value of non-glycated BSA; ##P < 0.01 compared
to the value of AGE-BSA. (D) Cells were preincubated with or without 1 mmol/L NAC 30 minutes prior to the treatment with 50 to 100 lg/mL
of carboxymethyllysine (CML)-BSA or nonglycated BSA for 48 hours. Then Ang II levels were measured. ∗P < 0.01 compared to the value of
nonglycated BSA; ##P < 0.05 compared to the value of CML-BSA.
significantly inhibited by either CML or non-CML AGEs
antibody.
Effects of AGEs on Ang II production
As shown in Figure 2A and B, AGEs increased Ang
II production in a time- and dose-dependent manner. To
examine the functional involvement of ROS generation
in AGE-elicited Ang II production, we studied the effect
of an antioxidant, NAC, on Ang II generation in AGE-
exposed mesangial cells. As shown in Figure 2C, NAC
completely inhibited the increase in Ang II generation in
AGE-exposed mesangial cells. CML-BSA also increased
Ang II production in mesangial cells, which was com-
pletely inhibited by NAC (Fig. 2D).
Effects of AGEs on TGF-b expression and its
downstream signaling
Ang II has been shown to stimulate expression of TGF-
b in various types of cells, including mesangial cells [9,
10, 45]. Therefore, we investigated whether AGEs could
stimulate TGF-b expression through autocrine produc-
tion of Ang II. As shown in Figure 3A, AGEs increased
TGF-b production by mesangial cells, which was com-
pletely prevented by 10−7 mol/L of an AT1R antagonist
candesartan.
In order to confirm that TGF-b actually activated the
downstream signaling pathway in AGE-exposed mesan-
gial cells, the effects of AGEs on Smad2 phospho-
rylation and TGF-b–inducible promoter activity were
assessed. As shown in Figure 3B and E, AGEs increased
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Fig. 3. Effects of advanced glycation end products (AGEs) on transforming growth factor-b (TGF-b) expression and its downstream signaling in
mesangial cells. (A) Total TGF-b expression. Mesangial cells were incubated with 100 lg/mL of AGE-bovine serum albumin (BSA) or 100 lg/mL
of nonglycated BSA in the presence or absence of 10−7 mol/L candesartan for 48 hours. Then total TGF-b production in mesangial cells were
determined. (B to D) Phosphorylation of Smad2 protein expression. Mesangial cells were incubated with 100 lg/mL of nonglycated BSA, 100 lg/mL
of AGE-BSA (B), 50 to 100 lg/mL of carboxymethyllysine (CML)-BSA (C), 500 lg/mL of purified AGEs from end-stage diabetic nephropathy
patient (AGE-frac) or 500 lg/mL of purified AGEs from normal volunteer (normal-frac) (D) in the presence or absence of 10−7 mol/L candesartan
or 10 lg/mL of polyclonal antibody (Ab) against TGF-b (TGF-b Ab) for 48 hours. Then phosphorylated Smad2 (p-Smad2) protein expression
was determined and the relative ratio to the b-actin expression was shown. (E) Mesangial cells were transfected with a luciferase-reporter plasmid
containing the TGF-b–inducible promoter (CAGA)12, and then treated with 100 lg/mL of AGE-BSA, 100 lg/mL of nonglycated BSA, or 10 ng/mL
of TGF-b in the presence or absence of 10−7 mol/L candesartan or 10 lg/mL of TGF-b Ab for 48 hours. Then luciferase activity was measured. ∗P <
0.05, ∗∗P < 0.01 compared to the value of nonglycated BSA; #P < 0.05, ##P < 0.01 compared to the value of AGE-BSA, CML-BSA, or AGE-frac.
Smad2 phosphorylation and TGF-b–inducible promoter
activity in mesangial cells, these effects were completely
blocked by treatment with either candesartan or the
polyclonal antibody against TGF-b . Both CML-BSA
(Fig. 3C) and AGE proteins purified from diabetic
patients on hemodialysis (Fig. 3D) also stimulated
Smad2 phosphorylation, which were also blocked by
candesartan.
Effects of AGEs on DNA and protein synthesis
As shown in Figure 4, AGEs significantly inhibited
DNA synthesis and stimulated de novo protein synthesis
in mesangial cells. Furthermore, AGEs up-regulated the
expression of the cyclin-dependent kinase inhibitor, p27,
in mesangial cells (Fig. 5). Both candesartan and the poly-
clonal antibody against TGF-b completely prevented the
AGE-induced decrease in DNA synthesis and increase in
protein synthesis associated with p27 overexpression.
Effects of AGEs on fibronectin production
AGEs significantly increased fibronectin production
by mesangial cells, and this was completely inhibited by
candesartan or the polyclonal antibody against TGF-b
(Fig. 6).
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Fig. 4. Effects of advanced glycation end
products (AGEs) on DNA and protein syn-
thesis in mesangial cells. Mesangial cells were
incubated with 100 lg/mL of AGE-bovine
serum albumin (BSA) or nonglycated BSA
in the presence or absence of 10−7 mol/L can-
desartan or 10 lg/mL of polyclonal antibody
(Ab) against transforming growth factor-b
(TGF-b) (TGF-b Ab) for 24 hours. Cells were
treated with 5-bomo-2′-deoxyuridine (BrdU)
(A) or [3H]leucine (B) for the last 16 hours of
incubation, and their incorporations into the
cells were measured. ∗P < 0.05, ∗∗P < 0.01
compared to the value of nonglycated BSA.
#P < 0.05, ##P < 0.01 compared to the value
of AGE-BSA.
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Fig. 5. Effects of advanced glycation end products (AGEs) on p27 ex-
pression in mesangial cells. Mesangial cells were treated with the indi-
cated concentrations of AGE-bovine serum albumin (BSA) or nong-
lycated BSA in the presence or absence of 10−7 mol/L candesartan
or 10 lg/mL of polyclonal antibody (Ab) against transforming growth
factor-b (TGF-b) (TGF-b Ab) for 48 hours. Then p27 protein expres-
sion was determined and the relative ratio to the b-actin expression was
shown. ∗P < 0.05 compared to the value of nonglycated BSA; #P < 0.05
compared to the value of AGE-BSA.
Effects of AGEs on RAGE expression
We previously have shown that AGEs increase RAGE
expression in microvascular endothelial cells and per-
icytes [46, 47]. As shown in Figure 7, AGEs signifi-
cantly increased RAGE expression in mesangial cells.
Furthermore, this increased RAGE expression was com-
pletely inhibited by candesartan or the polyclonal an-
tibody against TGF-b . Moreover, exogenously applied
TGF-b also was found to significantly up-regulate RAGE
expression in mesangial cells.
DISCUSSION
In the present study, we have demonstrated for the
first time that AGEs increase intracellular ROS gen-
eration in cultured mesangial cells by an interaction
with RAGE and the subsequent stimulation of Ang
II production. Since candesartan, an AT1R antagonist,
completely inhibited TGF-b overexpression, Smad2
phosphorylation and TGF-b–inducible promoter activ-
ity in AGE-exposed mesangial cells, AGE-induced ac-
tivation in TGF-b-Smad signaling pathways could be
mainly mediated by autocrine production of Ang II.
New and original findings in the present study are that
the AGE-RAGE interaction in mesangial cells acti-
vates TGF-b–Smad signaling pathways and subsequently
induces mesangial cell hypertrophy and fibronection
synthesis through autocrine Ang II generation via ROS
overproduction. So, our present study suggests that AT1R
antagonist could act as a blocker of the AGE-RAGE
signaling as well, thus providing a novel mechanistic
explanation for understanding why this type of drugs has
beneficial effects on diabetic nephropathy.
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Fig. 6. Effects of advanced glycation end products (AGEs) on fi-
bronectin synthesis in mesangial cells. Mesangial cells were treated with
the indicated concentrations of AGE-bovine serum albumin (BSA) or
nonglycated BSA in the presence or absence of 10−7 mol/L candesartan
or 10 lg/mL of polyclonal antibody (Ab) against transforming growth
factor-b (TGF-b) (TGF-b Ab) for 48 hours. Then fibronectin expres-
sion in mesangial cells was measured and the relative ratio to the b-actin
expression was shown. ∗P < 0.05, ∗∗P < 0.01 compared to the value of
nonglycated BSA; #P < 0.05 compared to the value of AGE-BSA.
Previously it has been shown that RAGE overexpress-
ing diabetic mice exhibit progressive glomerulosclerosis
with renal dysfunction, when compared with diabetic lit-
termates lacking the RAGE transgene [48]. The present
study has extended our previous works; the AGE-RAGE
interaction in mesangial cells could also be involved in
the development and progression of diabetic glomeru-
losclerosis by activating the Ang II-TGF-b–Smad signal-
ing pathway.
Recent studies in human and experimental models
of diabetes suggest that oxidative stress plays an im-
portant role in the pathogenesis of diabetic vascular
complications, including diabetic nephropathy [49]. In-
deed, high glucose up-regulates TGF-b and fibronectin
mRNA levels and protein synthesis in cultured mesangial
cells through nuclear factor-jB (NF-jB) and activator
protein-1 via ROS generation [50]. Further, antioxidants
have been shown to prevent glomerular hypertrophy, al-
buminuria, and renal expression of ECM proteins in ex-
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Fig. 7. Effects of advanced glycation end products (AGEs) on receptor
for AGE (RAGE) expression in mesangial cells. Mesangial cells were
treated with 100 lg/mL of AGE-bovine serum albumin (BSA), 100
lg/mL of nonglycated BSA, or 10 ng/mL of transforming growth factor-
b (TGF-b) in the presence or absence of 10−7 mol/L candesartan or 10
lg/mL of polyclonal antibody (Ab) against TGF-b (TGF-b Ab) for
48 hours. Then RAGE expression in mesangial cells was determined
and the relative ratio to the b-actin expression was shown. ∗∗P < 0.01
compared to the value of nonglycated BSA; #P < 0.05 compared to the
value of AGE-BSA.
perimental diabetes [51–53]. Since ACE is known to be
up-regulated by redox-sensitive mechanisms in vascular
wall cells [54], ROS generation elicited by AGE-RAGE
interaction may stimulate Ang II production by stimulat-
ing ACE activity in mesangial cells.
Early diabetic nephropathy is characterized by
glomerular hypertrophy, which is associated with mesan-
gial cell cycle arrest in the late G1 phase [55–57]. Among
the cyclin-dependent kinase inhibitors that cause G1 ar-
rest, p27 has been reported to be necessary for high
glucose-induced mesangial cell hypertrophy [55–57]. In
the present study, we identified that AGEs induced
mesangial cell hypertrophy through an up-regulation of
p27 expression. Since a decrease in DNA synthesis and an
increase in de novo protein synthesis, which is an index
of cell hypertrophy, is associated with p27 overexpres-
sion were completely prevented by candesartan or poly-
clonal antibody against TGF-b , AGE-induced mesangial
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Fig. 8. Hypothetic pathways of advanced gly-
cation end products (AGE)-mediated mesan-
gial alterations in diabetic nephropathy. The
picture depicts the functional relationship
among the AGE-receptor for AGE (RAGE)
interaction, reactive oxygen species (ROS)
generation, local renin-angiotensin system,
and transforming growth factor-b (TGF-b)
signaling in mesangial cells, implicating the
deleterious effects of the AGEs in the patho-
genesis of diabetic nephropathy, which may
form a vicious circuit.
cell hypertrophy may be primarily mediated by autocrine
Ang II production and subsequent activation of TGF-b
signaling. In support of this hypothesis, ACE inhibitor
treatment reduces glomerular p27 expression and hyper-
trophy in diabetic rats [57], and TGF-b–induced cellular
hypertrophy is attenuated in p27 null cells [58]. Recently,
the lack of p27 has been shown to ameliorate glomeru-
lar hypertrophy and albuminuria in diabetic mice despite
overexpression of TGF-b , further supporting the concept
that p27 is a key downstream mediator of mesangial hy-
pertrophy elicited by TGF-b [58].
Advanced diabetic nephropathy is characterized by
a progressive accumulation of ECM protein within the
glomerular mesangium and the tubulointerstitium [59].
There is a growing body of evidence suggesting that the
RAS and TGF-b systems are involved in the pathogen-
esis of diabetic glomerulosclerosis [60]. In the present
study, AGEs stimulated fibronectin production in cul-
tured mesangial cells, and this effect was completely pre-
vented by candesartan or a polyclonal antibody against
TGF-b . Blockade of the RAS by ACE inhibitors ame-
liorates structural and functional abnormalities in asso-
ciation with inhibition of TGF-b overexpression [61–63].
Furthermore, it has been demonstrated that chronic treat-
ment with a monoclonal antibody directed against TGF-b
prevents glomerulosclerosis and renal insufficiency in di-
abetic mice [11]. Therefore, it is postulated that AGE-
RAGE–mediated ROS generation participates in the
development of glomerulosclerosis by activating Ang II-
TGF-b signaling pathways with subsequent effects in in-
ducing increased ECM expression.
In our study, AGEs per se were noted to enhance
RAGE expression in cultured mesangial cells. Further-
more, this effect on RAGE was completely prevented
by candesartan or a polyclonal antibody against TGF-b .
Consistent with these findings, we have previously re-
ported that AGEs up-regulated RAGE gene expression
in microvascular endothelial cells through the redox-
sensitive transcriptional factor, NF-jB [46]. Since we
also observed that exogenous TGF-b stimulates RAGE
expression, it is predicted that AGE-RAGE–mediated
ROS generation followed by TGF-b activation forms a
mutually amplifying circuit (Fig. 8). Recently, the ACE in-
hibitor, ramipril, and the AT1R antagonist, lomesartan,
were both reported to inhibit the accumulation of AGEs
in experimental diabetic nephropathy, possibly via reduc-
ing the generation of oxidation products [64, 65], provid-
ing further support for this pathway.
The present study provides a novel functional rela-
tionship among the AGE-RAGE interaction, ROS gen-
eration, the local RAS, and TGF-b signaling in the
pathogenesis of diabetic nephropathy. It is hypothesized
that deleterious effects of the AGE-RAGE interaction in
diabetic nephropathy can be ascribed to intra-renal acti-
vation of the RAS-TGF-b signaling pathways, which is
possibly mediated via increased oxidative stress.
We have previously shown that the structural epitope
of in vitro-modified AGE-BSA actually existed in vivo in
serum of diabetic patients, and that the concentration of
AGEs used in this experiment was comparable with that
of in vivo situation of diabetes [35]. Further, the ROS gen-
eration elicited by diabetic patients-derived AGEs was
completely inhibited by the combination treatments of
both neutralizing antibodies against CML and non-CML
AGEs. These results suggest that AGE proteins purified
from diabetic patients show the same biologic effects on
mesangial cells, thus supporting the physiologic relevance
of in vitro-prepared AGEs in vivo. Two types of AGEs
(i.e., CML and non-CML AGEs) have been identified in
diffuse and nodular lesion in human diabetic nephropa-
thy [66, 67]. Since CML is one of ligands for RAGE
[44], we also found that either CML or non-CML AGE
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components in our AGE preparations have the biologic
activities on mesangial cells on the basis of the following
evidence. First, CML-BSA increased ROS generation in
a dose-dependent manner. Second, CML-BSA increased
Ang II production in mesangial cells, which was com-
pletely inhibited by an antioxidant, NAC. Third, CML-
BSA induced Smad2 phosphorylation, which was also
blocked by an AT1R, candesartan. Fourth, neutralizing
antibodies against CML or non-CML AGEs, partially,
but significantly, inhibited the ROS generation in mesan-
gial cells. Finally, the effects of combination of both anti-
bodies on the ROS generation were additive. It remains
to be determined if these in vitro findings in mesangial
cells ultimately occur in the diabetic kidney. However,
these results emphasize the important interrelationships
that occur between metabolic and hemodynamic path-
ways and provide important targets to optimize renopro-
tection in diabetes.
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